Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

• Drug: PF-04965842 100 mg
  
  PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
• Drug: PF-04965842 200 mg
  
  PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
• Drug: Placebo
  
  Placebo, administered as two tablets to be taken orally once daily for 12 weeks

• Experimental: PF-04965842 100 mg
  
  Intervention: Drug: PF-04965842 100 mg
• Experimental: PF-04965842 200 mg
  
  Intervention: Drug: PF-04965842 200 mg
• Placebo Comparator: Placebo
  
  Intervention: Drug: Placebo

Inclusion Criteria:

• 12 years of age or older with a minimum body weight of 40 kg
• Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS severity 4)
• Recent history of inadequate response or inability to tolerate topical AD treatments or require systemic treatments for AD control

Exclusion Criteria:

• Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study
• Prior treatment with JAK inhibitors
• Other active nonAD inflammatory skin diseases or conditions affecting skin
• Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
• Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception